Suneel Gupta, Chief Development Officer of Protagonist Therapeutics Inc (PTGX, Financial), executed a sale of 5,000 shares in the company on January 9, 2024, according to a recent SEC Filing. The transaction was carried out at an average price of $25 per share, resulting in a total value of $125,000.
Protagonist Therapeutics Inc is a biopharmaceutical company that discovers and develops peptide-based new chemical entities to address significant unmet medical needs. The company's focus is on gastrointestinal diseases and iron-related disorders.
Over the past year, the insider has sold a total of 5,000 shares and has not made any purchases of the company's stock.
The insider transaction history for Protagonist Therapeutics Inc indicates a pattern of 0 insider buys and 3 insider sells over the past year.
On the date of the insider's recent transaction, shares of Protagonist Therapeutics Inc were trading at $25, giving the company a market cap of $1.4085 billion.
With the stock price at $25 and a GuruFocus Value of $36.58, Protagonist Therapeutics Inc has a price-to-GF-Value ratio of 0.68, suggesting that the stock might be a Possible Value Trap, Think Twice according to its GF Value.
The GF Value is an intrinsic value estimate that takes into account historical trading multiples, a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
